Evidence map›Paper›PMID 41238945›Full record

SynthesisAnnals of hematology2025

Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.

Eman Ayman Nada, Mohamed Abdelhalim Elfagieh, Fares Abdelsalam, Asmaa Ahmed Elrashedy, Fatima A Idres, Abdelrahman Shata, Ali M Othman, Hasan Mohammad Masoum Hamoud, Radwa Mohamed Awadalla, Israa Ahmed Qutob and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eman Ayman NadaFaculty of Pharmacy, Tanta University, Gharbia, Egypt. emananada23@gmail.com.ORCID http://orcid.org/0000-0003-4313-1513
Mohamed Abdelhalim ElfagiehMisrata Faculty of medicine University, National Cancer institute, Misrata, Libya.ORCID http://orcid.org/0000-0002-5190-2763
Fares AbdelsalamMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.ORCID http://orcid.org/0000-0001-6879-1652
Asmaa Ahmed ElrashedyFaculty of Medicine, Kafr El-Shaikh University, Kafr el-Sheikh, Egypt.ORCID http://orcid.org/0000-0002-8312-3959
Fatima A IdresAl Baath University Faculty of Medicine, Homs, Syria.ORCID http://orcid.org/0000-0003-4677-9980
Abdelrahman ShataMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.ORCID http://orcid.org/0009-0008-0704-6585
Ali M OthmanFaculty of Medicine, Kafr El-Shaikh University, Kafr el-Sheikh, Egypt.
Hasan Mohammad Masoum HamoudFaculty of Dentistry, University of Kalamoon, Deir Atieh, Syria.ORCID http://orcid.org/0000-0002-9122-7280
Radwa Mohamed AwadallaFaculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-6901-6946
Israa Ahmed QutobMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.ORCID http://orcid.org/0009-0005-2173-9984
Belal Mohamed HamedMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by increased red blood cell production, with high risk of venous and arterial thrombosis. Mutations in the JAK2 gene, particularly JAK2 V617F, play a central role in its pathogenesis. Ropeginterferon alfa-2b is a novel long-acting interferon showing promise in managing PV through hematologic and molecular control.This study aimed to evaluate the efficacy and safety of Ropeginterferon alfa-2b in patients with PV based on a systematic review and meta-analysis of available clinical trials.A systematic search was conducted across PubMed, Cochrane Library, Web of Science, Google Scholar, and Scopus on May 8, 2025. Randomized controlled trials (RCTs) assessing Ropeginterferon alfa-2b in PV were included. The PRISMA guidelines were followed, and the protocol was registered in PROSPERO (CRD420251051466). Quality assessment was performed using RoB 2.0 and ROBINS-I tools. A random-effects model was applied using R software.Eight studies involving 761 patients were included and only six studies included in single arm meta-analysis with 328 patients. The pooled proportion of complete hematological response at 12 months was 0.63 (95% CI [0.51-0.73]), with high heterogeneity. Reductions in JAK2 V617F allele burden were significant (MD: 26.57, 95% CI [13.49-39.65]). Molecular response was achieved in 25% (95% CI [0.04-0.70]) of patients. The most common adverse events were elevated liver enzymes (AST: 0.28; ALT: 0.32), influenza-like illness (0.11), and anemia (0.09), with unresolved heterogeneity in all outcomes.Ropeginterferon alfa-2b shows promising efficacy in achieving hematological and molecular responses in patients with PV. However, notable heterogeneity and safety concerns, particularly liver-related adverse effects, warrant further investigation in large-scale trials.

Indexed as

Interferon-alphaInterferon alpha-2Polycythemia VeraPolyethylene GlycolsHumansJanus Kinase 2Randomized Controlled Trials as TopicRecombinant ProteinsTreatment OutcomeInterferon-alphaInterferon alpha-2JAK2 protein, humanJanus Kinase 2peginterferon alfa-2bPolyethylene GlycolsRecombinant Proteins

Identifiers

PMID41238945
PMCPMC12764608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.